Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC).
Julien Taïeb
Consultant or Advisory Role - Merck KGaA; Roche/Genentech; Sanofi
Honoraria - Amgen; Merck KGaA; Roche/Genentech; Sanofi
Josep Tabernero
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; ImClone Systems; Lilly; Merck KGaA
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi
Enrico Mini
No relevant relationships to disclose
Fabien Subtil
No relevant relationships to disclose
Gunnar Folprecht
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Merck KGaA; Roche/Genentech; Sanofi
Honoraria - Amgen; Bristol-Myers Squibb; Merck KGaA; Novartis; Roche/Genentech; Sanofi
Research Funding - Merck KGaA; Pfizer; Sanofi
Jean-Luc Van Laethem
No relevant relationships to disclose
Joseph Thaler
Honoraria - Merck Serono; Sanofi
Research Funding - Merck Serono
John A. Bridgewater
Consultant or Advisory Role - Roche
Honoraria - Merck
Evaristo Sanches
No relevant relationships to disclose
Lone Petersen
No relevant relationships to disclose
Laurence Collette
No relevant relationships to disclose
Eric Van Cutsem
Research Funding - Merck Serono
Karine Le Malicot
No relevant relationships to disclose
Philippe Rougier
Honoraria - Merck; Sanofi
Ramon Salazar
No relevant relationships to disclose
Laurent Bedenne
Honoraria - Amgen
Research Funding - Chugai Pharma; Pfizer
Jean Francois Emile
No relevant relationships to disclose
Pierre Laurent-Puig
Honoraria - Merck Serono
Come Lepage
No relevant relationships to disclose